Table I.
Clinical characteristics of patients with superficial vein thrombosis included in the study treated with dalteparin 10 000 IU (group A) and dalteparin 5000 IU (group B) (values are given as mean ± SD)
| Parameter | Whole group (n = 68) | Group A (n = 35) | Group B (n = 33) | P-value A vs. B |
|---|---|---|---|---|
| Age [years] | 60.2 ±11.2 | 59.4 ±11.7 | 61.3 ±10.8 | 0.42 |
| Sex (male) | 31 (46%) | 16 (46%) | 15 (46%) | 0.71 |
| Height [m] | 1.68 ±0.09 | 1.65 ±0.08 | 1.68 ±0.10 | 0.96 |
| Weight [kg] | 83.7 ±15.0 | 85.8 ±15.4 | 79.9 ±16.0 | 0.13 |
| BMI [kg/m2] | 29.9 ±5.1 | 31.2 ±4.7 | 28.6 ±5.3 | 0.08 |
| Systolic blood pressure [mm Hg] | 142.9 ±19.0 | 141.1 ±18.9 | 144.8 ±19.3 | 0.43 |
| Diastolic blood pressure [mm Hg] | 84.5 ±9.7 | 84.0 ±9.8 | 85.1 ±9.6 | 0.64 |
| Arterial hypertension | 20 (29.4%) | 14 (40.0%) | 6 (18.2%) | 0.06 |
| Diabetes mellitus | 1 (1.5%) | 1 (2.9%) | 0 (0%) | 0.34 |
| Hyperlipidemia | 12 (17.6%) | 7 (20.0%) | 5 (15.2%) | 0.52 |
| Smoking | 14 (20.5%) | 6 (17.1%) | 8 (24.2%) | 0.10 |
| Varicose veins | 52 (76 %) | 27 (77%) | 25 (76%) | 0.74 |
BMI – body mass index.